- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01642446
Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension
There is no consensus about the optimal treatment of hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, While this group of patients are classified as hepatectomy contraindication according to guidelines from National Comprehensive Cancer Network (NCCN) and American Association for the Study of Liver Diseases (AASLD). With improvement of surgical technique, preoperative evaluation, and perioperative management,especially the Precise Hepatectomy Technique, more and more studies confirmed the safety of surgical intervention to hepatocellular carcinoma (HCC) patients with cirrhotic portal hypertension.However, most of the previous studies were either retrospective or with small samples.
The investigators project is a prospective randomized controlled trial, planning to compare the safety, efficacy and quality of life between precise hepatectomy and combined interventional treatment on hepatocellular carcinoma (HCC) with cirrhotic portal hypertension, to make a further understanding of optimal strategy.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
GuangZhou, Guangdong, China, 510060
- Sun Yat-Sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of hepatocellular carcinoma patients, in accordance with HCC Professional Committee of the Chinese Anti-Cancer Association 2001 "Clinical Diagnosis of Primary Liver Cancer and Staging Criteria"
- solitary tumor ≤5cm, or three or fewer lesions none ≤3cm,As Milan criteria
- History of hepatitis B or HBsAg positive
- Cirrhosis and portal hypertension
- No treatment on liver cancer before
- KPS score ≥ 70
- The age of 18 to 65 years
- Child-Pugh A or B (Class B, scoring no more than 7 points)
Baseline laboratory test comply with the following criteria:
- White blood cell ≥ 1.0×109/L
- Platelet ≥ 25×109/L
- Hemoglobin ≥ 80g/L
- Serum ALT,AST ≤ 3×upper limit of normal (ULN)
- Serum creatinine ≤ 1.5 × ULN
- INR<1.5, or prothrombin time <ULN +4 sec
- Albumin ≥30g/L
- Total bilirubin ≤34mmol/L
- Informed consent with signature and time
- Good patient compliance
The surgical group patients received radical hepatectomy. Radical surgery is defined as: complete resection of visible tumor, R0 resection margins, and also including:
- The number of tumors is less than 3
- No tumor thrombus found in major branch of the portal veins, hepatics, inferior vena cava or bile duct
- No hepatic hilar lymph node metastasis
- No extrahepatic metastasis
Exclusion Criteria:
- extrahepatic metastasis; With metastasis in major branch of portal vein, hepatic vein
- History of hepatitis C or HCV-Ab positive
- Pugh Child-Pugh C, or with massive ascites or had a history of hepatic encephalopathy, or Upper digestive tract bleeding
- Poor physical condition or cachexia
- During the past 12 months just before the study, there had been any of the following: myocardial infarction, severe/unstable angina, coronary artery bypass graft surgery, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; arrhythmia according to the NCI-CTCAE ≥ grade 2, QTc interval extension (male> 450 ms, female> 470 ms);
- Renal insufficiency, need peritoneal dialysis or hemodialysis
- Serious dysfunction of other organs
- History of second primary malignant tumors
- Known or new evidence of brain or leptomeningeal disease
- Hemophilia or bleeding tendency, and are taking therapeutic doses of coumarin derivative anticoagulant therapy drugs
- Pregnant or lactation, all female patients with childbearing potential must have a pregnancy test (serum or urine) within 7 days after enrollment,and the result is negative
- History of organ transplantation
- Known HIV infection
- With any other serious acute and chronic physical or mental disease or abnormal laboratory tests, which are likely to increase risks or interfere with the interpretation of the results, or researchers believe that patients are not suitable for enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: surgery
Precise hepatectomy
|
Precise hepatectomy
|
Active Comparator: combined intervention
transcatheter hepatic arterial chemoembolization and/or ablation
|
transcatheter hepatic arterial chemoembolization and/or ablation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: 5 years
|
Overall survival is based on death from any cause, not just the condition being treated, thus it picks up death from side effects of the treatment, and effects on survival after relapse
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment complication
Time Frame: 90 days
|
defined as complications within the 90 days after treatment
|
90 days
|
Time to progress(TTP)
Time Frame: 3 years
|
TTP: The Hazard Ratio will be analyzed respectively with 95% confidence interval.
Meanwhile, Kaplan-Meier estimation and survival curves will be performed.
|
3 years
|
Disease control rate(DCR)
Time Frame: 3 years
|
Disease control rate: Calculate the disease control rate of the two treatment groups (disease control rate) and its 95% confidence interval, and make a descriptive analysis.
|
3 years
|
Quality of life(Qol)
Time Frame: 5 years
|
Quality of life: Follow the QOL-LC V2.0
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Hypertension
- Carcinoma
- Carcinoma, Hepatocellular
- Hypertension, Portal
Other Study ID Numbers
- 20125010Y
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma(HCC)
-
BayerNot yet recruitingHepatocellular Carcinoma (HCC)United States
-
Chugai PharmaceuticalRecruitingHepatocellular Carcinoma (HCC)Taiwan, Japan
-
Bristol-Myers SquibbCompletedHepatocellular Carcinoma (HCC)France, Korea, Republic of, Taiwan, United States, Singapore, Philippines, Malaysia, Hong Kong
-
Institut für Klinische Krebsforschung IKF GmbH...Active, not recruitingHepatocellular Carcinoma (HCC)Germany
-
Boston Scientific CorporationBiocompatabilities UK LtdWithdrawnHepatocellular Carcinoma (HCC)
-
University Hospital, BordeauxCompleted
-
Shanghai Zhongshan HospitalWest China Hospital; Tongji Hospital; Anhui Provincial HospitalUnknownHepatocellular Carcinoma (HCC)China
-
Medical College of WisconsinNorthwestern University; GuerbetCompletedHepatocellular Carcinoma (HCC)United States
-
University Hospital, MontpellierCompleted
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)China, Singapore
Clinical Trials on Precise hepatectomy
-
Bispebjerg HospitalHolbaek Sygehus; University of Zealand HospitalActive, not recruitingPregnancy Complications | Preterm Birth | Pregnancy Related | Small for Gestational Age at DeliveryDenmark
-
Beijing Tsinghua Chang Gung HospitalRecruitingPain, Chronic | Pain, IntractableChina
-
Shuguo Zheng, MDCompleted
-
Maastricht University Medical CenterCatharina Ziekenhuis Eindhoven; Universitair Ziekenhuis Brussel; General Hospital... and other collaboratorsCompletedCritical Illness | Intensive Care Unit Acquired WeaknessBelgium, Netherlands
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Sun Yat-sen UniversityMinistry of Health, ChinaCompletedHepatocellular Carcinoma | Hepatectomy | ChemoembolizationChina
-
The Netherlands Cancer InstituteUnknown
-
Peking Union Medical College HospitalCompletedTransverse Facial Cleft
-
China-Japan Friendship HospitalRecruiting